Citius Oncology Inc(CTOR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:00 PM ET (Korea 9/12 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.47 | Insider Own | 71.95% | Shs Outstand | 105.8M | Perf Week | 17.01% |
| Market Cap | 0.08B | Forward P/E | 9.1 | EPS next Y | 117.86% | Insider Trans | - | Shs Float | 26.1M | Perf Month | 24.66% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.19 | Inst Own | 15.21% | Short Float | 1.73% | Perf Quarter | 32.5% |
| Income | -0.05B | P/S | 11.9 | EPS this Y | -64.71% | Inst Trans | 0.41% | Short Ratio | 5.73 | Perf Half Y | -2.47% |
| Sales | 0.01B | P/B | 2.38 | EPS next 5Y | - | ROA | -45.2% | Short Interest | 0.45M | Perf YTD | -9% |
| Book/sh | 0.38 | P/C | 5.11 | EPS past 3/5Y | - -309.67% | ROE | -126.58% | 52W High | -59.56% ($2.25) | Perf Year | -51.34% |
| Cash/sh | 0.18 | P/FCF | - | Sales past 3/5Y | - | ROIC | -91.04% | 52W Low | 85.26% ($0.49) | Perf 3Y | -91.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -148.79% | Gross Margin | 28.92% | Volatility(W/M) | 10.08% 9.63% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 11.01 | Sales Y/Y TTM | - | Oper. Margin | -665.63% | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | -10.27% | Profit Margin | -648.32% | RSI (14) | 64.3 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.73 | Sales Q/Q | - | SMA20 | 13.25% ($0.8) | Beta | 3.42 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.25 | Earnings | 2026/8/14 | SMA50 | 26.58% ($0.72) | Rel Volume | 0.61 | Prev Close | $0.94 |
| Employees | - | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | -14.29% -40.25% | SMA200 | 2.01% ($0.89) | Avg Volume(3M) | 0.08M | Price | $0.91 |
| IPO | 2022/12/8 | Option/Short | No/Yes | Trades | 225 | Volume | 47,935 | Change | -3.19% |
Company
CTOR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A U.S.-based specialty pharmaceutical company developing and commercializing innovative immuno-oncology treatments for rare hematologic cancers. Through its recently FDA-approved therapy 'LYMPHIR™', the company is delivering a next-generation treatment alternative for patients with refractory cutaneous T-cell lymphoma (CTCL).
Over the past 1 year, on the lower side
60% below its 1-year high.
CTOR has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -64.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -91.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 15.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
SMH 71.1B
SOXX 45.4B
DYNF 41.7B
AVEM 28.7B
DRAM 26.9BIt ranks #4 in the industry
Based on market cap of $85M.
CTOR $85M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is CTOR?
CTOR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CTOR?
The market cap of CTOR is approximately $85M, ranking 4,661 within its sector.
What is the 52-week high and low for CTOR?
CTOR has recorded a 52-week high of $2.25 and a low of $0.49.
